| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5407914 | LEES PHARM HK | Pulmonary surfactant protein and related polypeptides |
Nov, 2013
(10 years ago) | |
Surfaxin is owned by Lees Pharm Hk.
Surfaxin contains Lucinactant.
Surfaxin has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Surfaxin are:
- US5407914
Surfaxin was authorised for market use on 06 March, 2012.
Surfaxin is available in suspension;intratracheal dosage forms.
Surfaxin can be used as prevention of respiratory distress (rds) in premature infants.
The generics of Surfaxin are possible to be released after 17 November, 2013.
Drugs and Companies using LUCINACTANT ingredient
Market Authorisation Date: 06 March, 2012
Treatment: Prevention of respiratory distress (rds) in premature infants
Dosage: SUSPENSION;INTRATRACHEAL
More Information on Dosage
SURFAXIN family patents
